LexaGene Demonstrates a Simple and Inexpensive Multiplex PCR Chemistry with Shorter Lead Times for use on its MiQLab System First point-of-need, PCR system capable of using conventional probe-based chemistry or inexpensive, rapidly available SYBR Green chemistry BEVERLY, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- LexaGene...

LexaGene’s MiQLab Detects Common Bioreactor Contaminant up to 300 Times Faster than Conventional Methods Mycoplasmas are thought to contaminate 15-80% of cell cultures worldwideMiQLab rapidly detected 100% of the tested mycoplasma samples within two hours, with no false positivesMiQLab can be used inside...

LexaGene Retains Wolf Greenfield Intellectual Property Law Firm BEVERLY, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a molecular diagnostics company that develops a fully automated rapid pathogen...